Price: $ 1295
BMI View: Investment into Uganda's pharmaceuticals and healthcare sector by companies to meet the demand for healthcare services is an advisable business strategy - as highlighted by the high growth forecast in healthcare spending between 2012 and 2017. However, we note that there are downside risks to our forecast. These include low affordability levels, inadequate healthcare infrastructure and inefficient supply chain systems, which will ultimately inhibit drugmakers' revenue-earning abilities. Headline Expenditure Projections ? Pharmaceuticals: UGX831.90bn (US$332mn) in 2012 to UGX926.84(US$348mn) in 2013; +11.4% growth in local currency terms and +4.2% in US dollar terms. ? Healthcare: UGX4,154.02bn (US$1.66bn) in 2012 to UGX4,504.76 (US$1.69bn) in 2013; 8.4% growth in local curren ...
Complete report details with Table of Contents and more @ http://www.marketreportsonline.com/270336.html
No comments:
Post a Comment